Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.57B -40.5% |
| Revenue (ttm) | 59.51M +12.6% |
| Net Income | -399.98M |
| EPS | -3.34 |
| Shares Out | 140.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,566,493 |
| Open | 11.00 |
| Previous Close | 11.16 |
| Day's Range | 10.58 - 11.24 |
| 52-Week Range | 7.95 - 26.35 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 23.11 (+106.16%) |
| Est. Earnings | Nov 5, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $23.11, which is an increase of 106.16% from the latest price.
News
Intellia Therapeutics appoints Jing Marantz as chief medical officer
Intellia Therapeutics (NTLA) announced the appointment of Jing Marantz as executive VP and chief medical officer, effective October 26. Marantz will lead the company’s translational, development, regu...
Intellia Therapeutics Appoints Jing L. Marantz, M.D.
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Barclays starts Intellia at Underweight on expected commercial headwinds
Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target The firm sees headwinds for the company’s late-stage assets in hereditary angioedema and tran...
Intellia Therapeutics initiated with an Underweight at Barclays
Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target
Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today
20:23 EDT Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Cathie Wood’s ARK Investment buys 411K shares of Intellia Therapeutics today
20:17 EDT Cathie Wood’s ARK Investment buys 411K shares of Intellia Therapeutics (NTLA) today
Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics today
20:44 EDT Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing in vivo gene editing with late-stage programs for HAE and TTR, expecting FDA approval for its HAE therapy by March 10. Strong efficacy and safety data support broad market potential, with a targeted commercial launch and robust financial runway enabling future pipeline investments.
Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today
20:05 EDT Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics price target raised to $13 from $12 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Intellia Therapeutics (NTLA) to $13 from $12 and keeps a Neutral rating on the shares. The firm notes the FDA…
Intellia Therapeutics announces FDA acceptance of lonvo-z BLA
Intellia Therapeutics (NTLA) announced the FDA has accepted the biologics license application for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world's first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE...
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional...
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
20:25 EDT Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today
Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today
20:17 EDT Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
As previously reported, Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NTLA) to Outperform from In Line with a price target of $24, up from $16, after the company “finally…
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform from In Line with a price target of $24, up from $16.
Intellia Therapeutics Earnings Call Transcript: Q2 2026
Major clinical progress was achieved in phase III programs for HAE and ATTR, with positive efficacy and safety data, a rolling BLA submission for lonvo-z, and resumed nex-z trials. Financially, cash reserves increased to $628.4 million, supporting operations into 2028.
Intellia Therapeutics Earnings release: Q2 2026
Intellia Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Intellia Therapeutics Quarterly report: Q2 2026
Intellia Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)
Reports Q2 revenue $7.66M, consensus $12.98M. “The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in…
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...